These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26463060)

  • 1. Pharmacokinetic Interactions for Drugs with a Long Half-Life—Evidence for the Need of Model-Based Analysis.
    Svensson EM; Acharya C; Clauson B; Dooley KE; Karlsson MO
    AAPS J; 2016 Jan; 18(1):171-9. PubMed ID: 26463060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis.
    Brill MJ; Svensson EM; Pandie M; Maartens G; Karlsson MO
    Int J Antimicrob Agents; 2017 Feb; 49(2):212-217. PubMed ID: 28038962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole.
    Lehr T; Staab A; Trommeshauser D; Schaefer HG; Kloft C
    Clin Pharmacokinet; 2010; 49(1):53-66. PubMed ID: 20000889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
    van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis.
    Maartens G; Brill MJE; Pandie M; Svensson EM
    Int J Tuberc Lung Dis; 2018 Jan; 22(1):26-29. PubMed ID: 29145924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB.
    Pandie M; Wiesner L; McIlleron H; Hughes J; Siwendu S; Conradie F; Variava E; Maartens G
    J Antimicrob Chemother; 2016 Apr; 71(4):1037-40. PubMed ID: 26747099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bedaquiline: a review of human pharmacokinetics and drug-drug interactions.
    van Heeswijk RP; Dannemann B; Hoetelmans RM
    J Antimicrob Chemother; 2014 Sep; 69(9):2310-8. PubMed ID: 24860154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
    Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
    Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug.
    Svensson EM; Murray S; Karlsson MO; Dooley KE
    J Antimicrob Chemother; 2015 Apr; 70(4):1106-14. PubMed ID: 25535219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs.
    Moltó J; Rajoli R; Back D; Valle M; Miranda C; Owen A; Clotet B; Siccardi M
    J Antimicrob Chemother; 2017 Mar; 72(3):805-811. PubMed ID: 27999009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.
    Guest EJ; Rowland-Yeo K; Rostami-Hodjegan A; Tucker GT; Houston JB; Galetin A
    Br J Clin Pharmacol; 2011 Jan; 71(1):72-87. PubMed ID: 21143503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steady-state pharmacokinetics of etravirine and lopinavir/ritonavir melt extrusion formulation, alone and in combination, in healthy HIV-negative volunteers.
    Schöller-Gyüre M; Kakuda TN; Witek J; Akuma SH; De Smedt G; Spittaels K; Vyncke V; Hoetelmans RM
    J Clin Pharmacol; 2013 Feb; 53(2):202-10. PubMed ID: 23436265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of pharmacokinetic interactions between long-acting HIV-1 fusion inhibitor albuvirtide and lopinavir/ritonavir, in HIV-infected subjects, combined with clinical study and simulation results.
    Yang W; Xiao Q; Wang D; Yao C; Yang J
    Xenobiotica; 2017 Feb; 47(2):133-143. PubMed ID: 27052428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
    Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
    Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis.
    Perrineau S; Lachâtre M; Lê MP; Rioux C; Loubet P; Fréchet-Jachym M; Gonzales MC; Grall N; Bouvet E; Veziris N; Yazdanpanah Y; Peytavin G
    Int J Tuberc Lung Dis; 2019 Jan; 23(1):99-104. PubMed ID: 30674381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone.
    Chen Y; Mao J; Hop CE
    Drug Metab Dispos; 2015 Feb; 43(2):182-9. PubMed ID: 25324279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A modeling-based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics study.
    Keutzer L; Akhondipour Salehabad Y; Davies Forsman L; Simonsson USH
    CPT Pharmacometrics Syst Pharmacol; 2022 May; 11(5):628-639. PubMed ID: 35102712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose- and Time-dependency of the Toxicity and Pharmacokinetic Profiles of Bedaquiline and Its N-desmethyl Metabolite in Dogs.
    Smyej I; De Jonghe S; Looszova A; Mannens G; Verhaeghe T; Thijssen S; Starckx S; Lampo A; Rouan MC
    Toxicol Pathol; 2017 Jul; 45(5):663-675. PubMed ID: 28789609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspectives from the Innovation and Quality Consortium Induction Working Group on Factors Impacting Clinical Drug-Drug Interactions Resulting from Induction: Focus on Cytochrome 3A Substrates.
    Ramsden D; Fung C; Hariparsad N; Kenny JR; Mohutsky M; Parrott NJ; Robertson S; Tweedie DJ
    Drug Metab Dispos; 2019 Oct; 47(10):1206-1221. PubMed ID: 31439574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.